直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

In Second CBM Decided, PTO Cancels All Claims, Ending Decade of Litigation

February 07, 2014

CRS Advanced Technologies, Inc. has invalidated all of a competitor’s relevant patent claims in CBM, ending a decade of litigation. Thus, the first two petitioners have won outright in the first two CBM decisions. The first decision found for SAP America, Inc. on all claims. Now, CRS Advanced Technologies, Inc. has likewise won, with the Board cancelling every claim pending in the litigation. See CRS Adv. Techs., Inc. v. Frontline Techs., Inc., CBM2012-00005, Paper 66 (PTAB Jan. 21, 2014).

The Board found the six asserted claims invalid for claiming an abstract idea. The patent, relating to “human resources management,” described “automating the performance of substitute fulfillment” and included a method and system claiming variously a database, information, an Internet communication link, a website, an organization worksite location, and one or more computers.

In analyzing § 101, the Board held that the machine-or-transformation test, while not the only test available, applied in this case. The Board continued: “cases have found claims to be directed to patent-ineligible subject matter where computing technology did not limit the scope of the claims meaningfully.” Analogizing the cases of Bancorp Services, L.L.C. v. Sun Life Assurance Co. of Canada; Dealertrack, Inc. v. Huber; and Accenture Global Servs., GmbH v. Guidewire Software, Inc., the Board found the process claims lacked particularized technology integral to the claimed subject matter. They found the “generic computer technology” to be more akin to ‘computer-aided’ as in the claims of Dealertrack, and the phrases ‘transaction database’ and ‘transmitting information’ to be akin to the unaccepted claims of Accenture. Thus, the Board held the method claims invalid.

Regarding the system claims, the Board held that including a “database” and a “system” “do not necessarily change the patent-eligibility analysis,” but rather, since the claims mirrored method claim 3, they fell with that claims’ fate. Thus, the Board cancelled the six asserted claims, ending almost ten years of litigation for CRS Advanced Technologies, Inc.

The decision capped a long journey for CRS. On February 10, 2004, Frontline sued CRS for patent infringement on the patent. Over ten years, the parties appeared in courts, the patent office central reexamination unit, and finally before the Board. In February 2013, the district court stayed the case—for a second time and close to trial—in light of the CBM proceeding. CRS v. Frontline emphasizes the effectiveness of post-grant review procedures when used strategically.

Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP